tbuckley/cabot-search huggingface dataset:
Clip-line-assisted underwater endoscopic mucosal resection for duodenal adenoma
Authors: Tatsuma Nomura, Haruka Nakamura, Shinya Sugimoto, Jun Oyamada, Keiichi Ito, Akira Kamei
Journal: Endoscopy (2022)

Recently, underwater endoscopic mucosal resection (U-EMR) has become established for treating duodenal adenomas. However, it is difficult to completely resect a large duodenal adenoma with en bloc resection [1]. An appropriate U-EMR method is desirable because the resection margin on the oral side is sometimes positive [2]. We devised a method for en bloc resection of large duodenal adenomas, called clip-line-assisted underwater endoscopic mucosal resection (CLU-EMR).
Preclinical and Clinical Demonstration of Immunogenicity by mRNA Vaccines against H10N8 and H7N9 Influenza Viruses
Authors: Kapil Bahl, Joe J. Senn, Olga Yuzhakov, Alex Bulychev, Luis A. Brito, Kimberly J. Hassett, Michael E. Laska, Mike Smith, Örn Almarsson, James Thompson, Amilcar (Mick) Ribeiro, Mike Watson, Tal Zaks, Giuseppe Ciaramella
Journal: Molecular Therapy (2022)

Main text(Molecular Therapy 25, 1316–1327; June 2017)In the originally published version of this article, the sentence “LNP formulations were prepared using a modified procedure of a method previously described for siRNA” incorrectly cited reference 57. The correct reference for this sentence is reference 22.The authors regret this error. Main text(Molecular Therapy 25, 1316–1327; June 2017)In the originally published version of this article, the sentence “LNP formulations were prepared using a modified procedure of a method previously described for siRNA” incorrectly cited reference 57. The correct reference for this sentence is reference 22.The authors regret this error. (Molecular Therapy 25, 1316–1327; June 2017) In the originally published version of this article, the sentence “LNP formulations were prepared using a modified procedure of a method previously described for siRNA” incorrectly cited reference 57. The correct reference for this sentence is reference 22. The authors regret this error. Preclinical and Clinical Demonstration of Immunogenicity by mRNA Vaccines against H10N8 and H7N9 Influenza VirusesBahl et al.Molecular TherapyApril 27, 2017In BriefPotential pandemic influenzas and the need for an effective, safe, and high-speed vaccine production platform have been widely discussed in the scientific community. Bahl et al. report the rapid and robust immune responses achieved against H10N8 and H7N9 viruses from modified mRNA vaccines with an acceptable safety profile. Full-Text PDF Open Access
Point-of-Care Cardiopulmonary Resuscitation Training and Survival With Favorable Neurologic Outcome in Cardiac Arrest in Pediatric ICUs—Reply
Authors: Ryan W. Morgan, Vinay M. Nadkarni, Robert M. Sutton
Journal: JAMA (2022)

In Reply We agree that clinicians and educators should interpret our study1 findings carefully and not conclude that these types of physiologic point-of-care CPR trainings and debriefings are ineffective based on a trial that was negative for the primary outcome.
Incidence of Acute Chest Syndrome in Children With Sickle Cell Disease Following Implementation of the 13-Valent Pneumococcal Conjugate Vaccine in France
Authors: Zein Assad, Morgane Michel, Zaba Valtuille, Andrea Lazzati, Priscilla Boizeau, Fouad Madhi, Jean Gaschignard, Luu-Ly Pham, Marion Caseris, Robert Cohen, Florentia Kaguelidou, Emmanuelle Varon, Corinne Alberti, Albert Faye, François Angoulvant, Bérengère Koehl, Naïm Ouldali
Journal: JAMA Network Open (2022)

Acute chest syndrome (ACS) is one of the leading acute severe complications of sickle-cell disease (SCD). Although Streptococcus pneumoniae (S pneumoniae) is highly prevalent in children with SCD, its precise role in ACS is unclear. The efficacy of 13-valent pneumococcal conjugate vaccine (PCV13) implementation on ACS is still unknown. To assess the association of PCV13 implementation in the general pediatric population with the incidence of ACS in children with SCD. This cohort study used an interrupted time-series analysis of patient records from a national hospital-based French surveillance system. All children younger than 18 years with SCD (based on the International Statistical Classification of Diseases and Related Health Problems, Tenth Revision definition) hospitalized in France between January 2007 and December 2019 were included. PCV13 implementation. Monthly incidence of ACS per 1000 children with SCD over time as analyzed by segmented linear regression with autoregressive error; monthly incidence of hospitalization for vaso-occlusive crisis, asthma crisis, and acute pyelonephritis per 1000 children with SCD over the same period as the control outcomes. Among the 107 694 hospitalizations of children with SCD, 4007 episodes of ACS were included (median [IQR] age, 8 [4-12] years; 2228 [55.6%] boys). PCV13 implementation in 2010 was followed by a significant decrease in the incidence of ACS (-0.9% per month; 95% CI, -1.4% to -0.4%; P < .001), with an estimated cumulative change of -41.8% (95% CI, -70.8% to -12.7%) by 2019. Sensitivity analyses yielded the same results, including the incidence of ACS adjusted for that of vaso-occlusive crisis over time. The results were similar among different age groups. By contrast, no change was found for the 3 control outcomes over the study period. PCV13 implementation was associated with an important reduction in the incidence of ACS in children with SCD. This vaccine benefit provides new evidence of the key role of S pneumoniae in ACS and should be considered when estimating outcomes associated with current PCVs and the potential benefit of next-generation PCVs in children.
Association of Higher-Dose Fluoroquinolone Therapy With Serious Adverse Events in Older Adults With Advanced Chronic Kidney Disease
Authors: Flory Tsobo Muanda, Manish M. Sood, Matthew A. Weir, Jessica M. Sontrop, Fatemeh Ahmadi, Elisa Yoo, Richard B. Kim, Michael S. Silverman, Gregory A. Knoll, Amit X. Garg
Journal: JAMA Network Open (2022)

Population-based data are needed to inform the safe prescribing of fluoroquinolone antibiotics to patients with advanced chronic kidney disease (CKD).To quantify the 14-day risk of a hospital visit with nervous system and/or psychiatric disorders, hypoglycemia, or a collagen-associated event in patients with advanced CKD newly prescribed a fluoroquinolone at a higher vs a lower dose.This population-based cohort study in Ontario, Canada (January 1, 2008, to March 17, 2020) used linked health care data to identify new users of fluoroquinolone antibiotics. Participants included adults 66 years or older with advanced CKD (an estimated glomerular filtration rate [eGFR] <30 mL/min/1.73 m2 but not receiving dialysis). Data analysis was performed from January 1 to April 30, 2021.A new prescription for a higher-dose fluoroquinolone (ciprofloxacin, 501-1000 mg/d; levofloxacin, 501-750 mg/d; or norfloxacin, 401-800 mg/d) vs a lower-dose fluoroquinolone (ciprofloxacin, 500 mg/d; levofloxacin, 250-500 mg/d; or norfloxacin, 400 mg/d).The primary outcome was the 14-day risk of a hospital visit with nervous system and/or psychiatric disorders, hypoglycemia, or a collagen-associated event. Secondary outcomes included a hospital visit with sepsis, retinal detachment or other tendinopathies, all-cause hospitalization, all-cause mortality, and sudden cardiac death. Inverse probability of treatment weighting on the propensity score was used to balance comparison groups on baseline health. Weighted risk ratios and risk differences were obtained using modified Poisson regression and binomial regression, respectively.Of 11 917 patients (median age, 83 years [IQR, 77-89 years]; 7438 women [62.4%]; median eGFR, 25 [IQR, 21-28] mL/min/1.73 m2) included in the analysis, 5482 (46.0%) received a higher-dose and 6435 (54.0%) received a lower-dose fluoroquinolone. After weighting, the primary composite outcome-a hospital visit with nervous system and/or psychiatric disorders, hypoglycemia, or a collagen-associated event-occurred in 68 of 5482 patients (1.2%) treated with a higher-dose fluoroquinolone and in 47 of 5516 (0.9%) treated with a lower-dose fluoroquinolone (weighted risk ratio, 1.45 [95% CI, 1.01-2.08]; weighted risk difference, 0.39% [95% CI, 0.01%-0.76%]). The risk of sepsis, retinal detachment, all-cause hospitalization, all-cause mortality, and sudden cardiac death did not differ significantly between groups.These findings suggest that older patients with advanced CKD who were prescribed a fluoroquinolone at a higher-than-recommended dose were significantly more likely to experience the composite outcome of a hospital visit with nervous system and/or psychiatric disorders, hypoglycemia, or a collagen-associated event, although the absolute risk of these events was less than 2%.
Apple Watch Parkinson Disease Symptom Monitor Is Cleared
Authors: Howard D. Larkin
Journal: JAMA (2022)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Point-of-Care Cardiopulmonary Resuscitation Training and Survival With Favorable Neurologic Outcome in Cardiac Arrest in Pediatric ICUs
Authors: William C. McGaghie, Jeffrey H. Barsuk, Diane B. Wayne
Journal: JAMA (2022)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Reported Interest in Notification Regarding Use of Health Information and Biospecimens
Authors: Kayte Spector-Bagdady, Grace Trinidad, Sharon Kardia, Chris D. Krenz, Paige Nong, Minakshi Raj, Jodyn E. Platt
Journal: JAMA (2022)

This study describes reported interest in notification regarding use of personal health information and biospecimens for research and preference-associated factors among a sample of the US population in 2019.
Effect of Graded Sensorimotor Retraining on Pain Intensity in Patients With Chronic Low Back Pain
Authors: Matthew K. Bagg, Benedict M. Wand, Aidan G. Cashin, Hopin Lee, Markus Hübscher, Tasha R. Stanton, Neil E. O’Connell, Edel T. O’Hagan, Rodrigo R. N. Rizzo, Michael A. Wewege, Martin Rabey, Stephen Goodall, Sopany Saing, Serigne N. Lo, Hannu Luomajoki, Robert D. Herbert, Chris G. Maher, G. Lorimer Moseley, James H. McAuley
Journal: JAMA (2022)

<h3>Importance</h3> The effects of altered neural processing, defined as altering neural networks responsible for perceptions of pain and function, on chronic pain remains unclear. <h3>Objective</h3> To estimate the effect of a graded sensorimotor retraining intervention (RESOLVE) on pain intensity in people with chronic low back pain. <h3>Design, Setting, and Participants</h3> This parallel, 2-group, randomized clinical trial recruited participants with chronic (&gt;3 months) nonspecific low back pain from primary care and community settings. A total of 276 adults were randomized (in a 1:1 ratio) to the intervention or sham procedure and attention control groups delivered by clinicians at a medical research institute in Sydney, Australia. The first participant was randomized on December 10, 2015, and the last was randomized on July 25, 2019. Follow-up was completed on February 3, 2020. <h3>Interventions</h3> Participants randomized to the intervention group (n = 138) were asked to participate in 12 weekly clinical sessions and home training designed to educate them about and assist them with movement and physical activity while experiencing lower back pain. Participants randomized to the control group (n = 138) were asked to participate in 12 weekly clinical sessions and home training that required similar time as the intervention but did not focus on education, movement, and physical activity. The control group included sham laser and shortwave diathermy applied to the back and sham noninvasive brain stimulation. <h3>Main Outcomes and Measures</h3> The primary outcome was pain intensity at 18 weeks, measured on an 11-point numerical rating scale (range, 0 [no pain] to 10 [worst pain imaginable]) for which the between-group minimum clinically important difference is 1.0 point. <h3>Results</h3> Among 276 randomized patients (mean [SD] age, 46 [14.3] years; 138 [50%] women), 261 (95%) completed follow-up at 18 weeks. The mean pain intensity was 5.6 at baseline and 3.1 at 18 weeks in the intervention group and 5.8 at baseline and 4.0 at 18 weeks in the control group, with an estimated between-group mean difference at 18 weeks of −1.0 point ([95% CI, −1.5 to −0.4];<i>P</i> = .001), favoring the intervention group. <h3>Conclusions and Relevance</h3> In this randomized clinical trial conducted at a single center among patients with chronic low back pain, graded sensorimotor retraining, compared with a sham procedure and attention control, significantly improved pain intensity at 18 weeks. The improvements in pain intensity were small, and further research is needed to understand the generalizability of the findings. <h3>Trial Registration</h3> ANZCTR Identifier:ACTRN12615000610538
Weight Loss Is Still Substantial a Decade After Bariatric Surgery
Authors: Anita Slomski
Journal: JAMA (2022)

Both laparoscopic sleeve gastrectomy (LSG) and laparoscopic Roux-en-Y gastric bypass (LRYGB) resulted in significant and sustainable weight loss among patients with severe obesity in a 10-year follow-up study of the SLEEVEPASS trial.
Integrity of SARS-CoV-2 Laboratory-Developed Tests
Authors: Jonathan R. Genzen, Jenna Rychert, Tracy I. George
Journal: JAMA (2022)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A Person-Centered Care Dashboard for Individuals With Complex Health Care Needs—Charting a Course for the Future
Authors: Sarah Hudson Scholle, Aanand D. Naik
Journal: JAMA Network Open (2022)

Evelyn T. Chang, MD, MSHS; Sydne Newberry, PhD; Lisa V. Rubenstein, MD, MSPH; Aneesa Motala, BA; Marika J. Booth, MS; Paul G. Shekelle, MD, PhD
Point-of-Care Cardiopulmonary Resuscitation Training and Survival With Favorable Neurologic Outcome in Cardiac Arrest in Pediatric ICUs
Authors: Yakun Liu, Wenjun Tu, Yajun Chen
Journal: JAMA (2022)

To the Editor We have some concerns about a recent trial1 that demonstrated that a bundled intervention of CPR training and postcardiac arrest debriefings did not improve patient survival to hospital discharge with favorable neurologic outcome among pediatric patients with cardiac arrest.
RNA Interference Therapy Approved for Hereditary Type of Amyloidosis
Authors: Howard D. Larkin
Journal: JAMA (2022)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Integrity of SARS-CoV-2 Laboratory-Developed Tests—Reply
Authors: Eli Y. Adashi, Glenn Cohen
Journal: JAMA (2022)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Association of Receiving a Fourth Dose of the BNT162b Vaccine With SARS-CoV-2 Infection Among Health Care Workers in Israel
Authors: Matan J. Cohen, Yonatan Oster, Allon E. Moses, Avishay Spitzer, Shmuel Benenson, Asala Abu-Ahmad, Yoel Angel, Ronen Ben-Ami, Debby Ben-David, Inon Buda, Michal Chowers, Ayelet Elbirt, Khetam Hussein, Chezi Levi, Yasmin Maor, Ran Nir-Paz, Alona Paz, Esther Saiag, Shlomo Maayan, Yael Shachor-Meyouhas, Pnina Shitrit, Miriam Weinberger, Yonit Wiener-Well, Adi Zaidman Shimshovitz, Eli Sprecher, Hiba Zayyad, Oren Zimhony
Journal: JAMA Network Open (2022)

<h3>Importance</h3> Despite the high 3-dose vaccination rate among health care workers (HCWs) in Israel, a high rate of SARS-CoV-2 breakthrough infections in this group was observed during the Omicron wave. As a result, the Israeli Ministry of Health decided to recommend a fourth vaccine dose to medical staff. <h3>Objective</h3> To evaluate the benefit of a fourth BNT162b2 vaccine dose on the breakthrough infection rate among HCWs. <h3>Design, Setting, and Participants</h3> This multicenter cohort study was performed in January 2022, the first month of the 4-dose vaccination campaign, during a surge of the Omicron variant wave. All health care workers at 11 general hospitals in Israel who had been vaccinated with 3 doses up to September 30, 2021, and had not contracted COVID-19 before the vaccination campaign were included. <h3>Exposures</h3> Vaccination with a fourth dose of the BNT162b2 vaccine during January 2022. <h3>Main Outcomes and Measures</h3> Breakthrough COVID-19 infections in 4-dose recipients vs 3-dose recipients measured by a polymerase chain reaction test result positive for SARS-CoV-2. Health care workers were tested based on symptoms or exposure. <h3>Results</h3> A total of 29 611 Israeli HCWs (19 381 [65%] female; mean [SD] age, 44 [12] years) had received 3 vaccine doses between August and September 2021; of these, 5331 (18%) received the fourth dose in January 2022 and were not infected by the first week after vaccination. Overall breakthrough infection rates were 368 of 5331 (7%) in the 4-dose group and 4802 of 24280 (20%) in the 3-dose group (relative risk, 0.35; 95% CI, 0.32-0.39). Similar reductions were found in a matched analysis by the exact day of receiving the third vaccine (relative risk, 0.61; 95% CI, 0.54-0.71) and in a time-dependent Cox proportional hazards regression model (adjusted hazard ratio, 0.56; 95% CI, 0.50-0.63). In both groups, no severe disease or death occurred. <h3>Conclusions and Relevance</h3> In this cohort study, the fourth BNT162b2 vaccine dose resulted in a reduced breakthrough infection rate among hospital staff. This reduction was lower than that observed after the third dose; nevertheless, considering the high infectivity of the Omicron variant, which led to critical medical staff shortages, a fourth vaccine dose should be considered to mitigate the infection rate among HCWs.
Errors in Data
Journal: JAMA Network Open (2022)

The Original Investigation titled "Assessment of Underuse and Overuse of Screening Tests for Co-occurring Conditions Among Children With Obesity," 1 published July 14, 2022, has been corrected to fix an error in data that affected the Abstract, Results, and Discussion, as well as Table 2.The number of children who received potentially unnecessary thyroid or insulin tests has been changed to 36 032 (23.0%).This article has been corrected.
National Estimates of Increase in US Mechanical Ventilator Supply During the COVID-19 Pandemic
Authors: Thomas C. Tsai, E. John Orav, Ashish K. Jha, Jose F. Figueroa
Journal: JAMA Network Open (2022)

This cross-sectional study assesses whether the increase in adult and pediatric and neonatal mechanical ventilators in US hospitals in response to the COVID-19 pandemic varied across hospital structural features, region, and safety-net status.